Patents Assigned to SERVIER PHARMACEUTICALS LLC
  • Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
    Patent number: 12679820
    Abstract: Provided are solid forms of a compound useful for treating cancer, pharmaceutical compositions thereof, and methods of treating cancer comprising administering the solid forms described herein to a patient in need thereof.
    Type: Grant
    Filed: November 8, 2023
    Date of Patent: July 14, 2026
    Assignee: Servier Pharmaceuticals LLC
    Inventors: Benjamin S. Lane, Chong-Hui Gu
  • THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE
    Publication number: 20260085059
    Abstract: Provided are compounds useful for treating of cancer and methods for treating of cancer, comprising administering to a subject in need thereof a compound described therein.
    Type: Application
    Filed: May 7, 2025
    Publication date: March 26, 2026
    Applicant: Servier Pharmaceuticals LLC
    Inventors: Samuel V. Agresta, Chong-Hui Gu, David Schenkein, Hua Yang, Liting Guo, Zhen Tang, Jianming Wang, Yanfeng Zhang, Yan Zhou
  • Method for preparing ivosidenib and an intermediate thereof
    Patent number: 12479824
    Abstract: The present application relates to a method for preparing a substantially and diastereomerically pure crystalline ethanol solvate of Compound IIa and its use for synthesizing Ivosidenib.
    Type: Grant
    Filed: August 7, 2020
    Date of Patent: November 25, 2025
    Assignee: SERVIER PHARMACEUTICALS LLC
    Inventors: Jacob Paul Sizemore, Shijie Zhang, Nha Huu Vo
  • Therapeutically active compounds and their methods of use
    Patent number: 12433895
    Abstract: Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
    Type: Grant
    Filed: October 5, 2023
    Date of Patent: October 7, 2025
    Assignee: Servier Pharmaceuticals LLC
    Inventors: Zenon D. Konteatis, Janeta Popovici-Muller, Jeremy M. Travins, Robert Zahler, Zhenwei Cai, Ding Zhou
  • Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof
    Patent number: 12297179
    Abstract: Provided herein are various salts, including tris(hydroxymethyl)aminomethane salts and sodium salts, as well as various crystalline forms of the compound represented by the structural formula: Also provided are pharmaceutical compositions comprising these salts and crystalline forms, methods for their manufacture, and uses thereof for treating conditions, including but not limited to conditions that would benefit from inhibition of dihydroorotate dehydrogenase (DHODH).
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: May 13, 2025
    Assignee: Servier Pharmaceuticals LLC
    Inventors: Jacob Sizemore, Shijie Zhang
  • Methods of use for trisubstituted benzotriazole derivatives
    Patent number: 12290508
    Abstract: The present invention provides methods for treating cancer in a subject with a trisubstituted benzotriazole derivative with the formula (I) or a pharmaceutically acceptable salt thereof, wherein the variables R1, R2 and R3 are as defined herein.
    Type: Grant
    Filed: June 9, 2023
    Date of Patent: May 6, 2025
    Assignee: Servier Pharmaceuticals LLC
    Inventors: Danielle Ulanet, Sung Eun Choe
  • Ivosidenib forms and pharmaceutical compositions
    Patent number: 12264148
    Abstract: Provided are formulations of ivosidenib including a number of polymorphs. Further provided are formulations of ivosidenib containing a number of known impurities. Still further provided are stable compositions of ivosidenib.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: April 1, 2025
    Assignee: Servier Pharmaceuticals LLC
    Inventors: Chong-Hui Gu, Jacob Paul Sizemore, Shijie Zhang
  • Methods of treating brain tumors using combination therapy
    Patent number: 12064436
    Abstract: Provided are methods of treating a brain tumor in a patient in need thereof comprising administering to the patient a compound described herein and radiation therapy and/or one or more additional therapeutic agents.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: August 20, 2024
    Assignee: Servier Pharmaceuticals LLC
    Inventors: Joshua Murtie, Nelamangala Nagaraja, Brandon Nicolay, David Schenkein, Katharine Yen
  • Methods of treating brain tumors using combination therapy
    Patent number: 12042497
    Abstract: Provided are methods of treating a brain tumor in a patient in need thereof comprising administering to the patient a compound described herein and radiation therapy and/or one or more additional therapeutic agents.
    Type: Grant
    Filed: August 25, 2020
    Date of Patent: July 23, 2024
    Assignee: Servier Pharmaceuticals LLC
    Inventors: Joshua Murtie, Nelamangala Nagaraja, Brandon Nicolay, David Schenkein, Katharine Yen
  • Therapeutically active compounds and their methods of use
    Patent number: 11865079
    Abstract: Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a purified compound described herein.
    Type: Grant
    Filed: February 10, 2022
    Date of Patent: January 9, 2024
    Assignee: Servier Pharmaceuticals LLC
    Inventor: Chandra Agarwal Prakash
  • Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
    Patent number: 11851417
    Abstract: Provided are solid forms of a compound useful for treating cancer, pharmaceutical compositions thereof, and methods of treating cancer comprising administering the solid forms described herein to a patient in need thereof.
    Type: Grant
    Filed: April 19, 2022
    Date of Patent: December 26, 2023
    Assignee: Servier Pharmaceuticals LLC
    Inventors: Benjamin S. Lane, Chong-Hui Gu
  • Therapeutically active compounds and their methods of use
    Patent number: 11844758
    Abstract: Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
    Type: Grant
    Filed: January 26, 2021
    Date of Patent: December 19, 2023
    Assignee: Servier Pharmaceuticals LLC
    Inventors: Zenon Konteatis, Janeta Popovici-Muller, Jeremy Travins, Robert Zahler, Zhenwei Cai, Ding Zhou
  • USE OF A DHODH INHIBITOR COMPOUND IN COMBINATION CANCER THERAPY
    Publication number: 20230285365
    Abstract: Provided herein are method of treating lymphomas using an anti-cancer agent and an anti-cancer therapy, wherein the first anti-cancer agent is represented by Formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 26, 2021
    Publication date: September 14, 2023
    Applicant: Servier Pharmaceuticals LLC
    Inventors: John Coco, Brandon Nicolay
  • Methods of use for trisubstituted benzotriazole derivatives
    Patent number: 11717512
    Abstract: The present invention provides methods for treating cancer in a subject with a trisubstituted benzotriazole derivative with the formula (I) or a pharmaceutically acceptable salt thereof, wherein the variables R1, R2 and R3 are as defined herein.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: August 8, 2023
    Assignee: Servier Pharmaceuticals LLC
    Inventors: Danielle Ulanet, Sung Eun Choe
  • Therapeutically active compounds and their methods of use
    Patent number: 11667673
    Abstract: Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: June 6, 2023
    Assignee: Servier Pharmaceuticals LLC
    Inventors: Janeta Popovici-Muller, Rene M. Lemieux, Jeremy Travins, Zhenwei Cai, Dawei Cui, Ding Zhou
  • Heterobicyclic inhibitors of MAT2A and methods of use for treating cancer
    Patent number: 11524960
    Abstract: The present disclosure provides for compounds according to Formula I or Formula II and their pharmaceutically acceptable salts, stereoisomers, and/or tautomers thereof. Also provided are pharmaceutical compositions and the compounds of formulae I and II for use in methods of treating cancers, via inhibition of MAT2A, including some cancers in which the gene encoding methylthioadenosine phosphorylase (MTAP) is deleted and/or not fully functioning.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: December 13, 2022
    Assignee: SERVIER PHARMACEUTICALS LLC
    Inventors: Zenon D. Konteatis, Mingzong Li, Peng Liu, Matthew Medeiros, Samuel K. Reznik, Zhihua Sui, Jeremy M. Travins, Janeta Popovici-Muller, Shubao Zhou, Guangning Ma
  • Pharmaceutical compositions of therapeutically active compounds
    Patent number: 11504361
    Abstract: Provided are compounds and pharmaceutical compositions useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound or pharmaceutical composition described herein.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: November 22, 2022
    Assignee: SERVIER PHARMACEUTICALS LLC
    Inventor: Chong-Hui Gu
  • Therapeutically active compounds and their methods of use
    Patent number: 11505538
    Abstract: Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
    Type: Grant
    Filed: June 18, 2020
    Date of Patent: November 22, 2022
    Assignee: Servier Pharmaceuticals LLC
    Inventors: Giovanni Cianchetta, Byron DeLaBarre, Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey O. Saunders, Jeremy Travins, Shunqi Yan, Tao Guo, Li Zhang
  • Combination therapy for treating malignancies
    Patent number: 11419859
    Abstract: Provided are methods and compositions for treating acute myelogenous leukemia (AML) in patients carrying an IDH1 mutation using an inhibitor of a mutant IDH1 enzyme, (S)—N—((S)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide in combination with cytarabine and doxorubicin or idarubicin as an induction therapy and either cytarabine or a combination of combination of mitoxantrone and etoposide as consolidation therapy.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: August 23, 2022
    Assignee: SERVIER PHARMACEUTICALS LLC
    Inventor: Samuel V. Agresta
  • Inhibitors of cellular metabolic processes
    Patent number: RE49934
    Abstract: The present disclosure provides MAT2A inhibitor compounds that are useful as therapeutic agents for treating malignancies, and wherein the compounds conform to general formula (IA): wherein RA, RB, RC, RD, and RE are defined herein.
    Type: Grant
    Filed: March 8, 2022
    Date of Patent: April 23, 2024
    Assignee: Servier Pharmaceuticals LLC
    Inventors: Zenon D. Konteatis, Zhihua Sui, Jeremy M. Travins, Zhixiong Ye